I6T-MC-AMBZ - A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502393-16-00

Acronym

I6T-MC-AMBZ

Enrollment

116

Registered

2023-07-17

Start date

2023-09-06

Completion date

Unknown

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderately to Severely Active Ulcerative Colitis

Brief summary

Change from baseline in bowel urgency severity (UNRS) score at Week 12.

Interventions

DRUGMirikizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in bowel urgency severity (UNRS) score at Week 12.	—

Countries

Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Slovakia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026